.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 7,741,268

« Back to Dashboard

Claims for Patent: 7,741,268

Title:Liquid pharmaceutical formulations of FSH and LH together with a non-ionic surfactant
Abstract:The invention relates to the field of pharmaceutical formulations of follicle-stimulating hormone (FSH), luteinising hormone (LH), and mixtures of FSH and luteinising hormone (LH), and to methods of producing such formulations. The invention provides a liquid or freeze-dried formulation of FSH, or LH, or FSH and LH comprising a surfactant selected from Pluronic.RTM. F77, Pluronic F87, Pluronic F88 and Pluronic F68.
Inventor(s): Samaritani; Fabrizio (Rome, IT), Donati; Piergiorgio (Morges, CH)
Assignee: Ares Trading S.A. (Aubonne, CH)
Application Number:10/551,840
Patent Claims: 1. A liquid pharmaceutical composition, comprising: a follicle stimulating hormone, m-cresol, a diluent, and poloxamer 188, the composition having a stability sufficient to avoid precipitation.

2. The composition according to claim 1, wherein the follicle stimulating hormone is present in an amount of from 150 IU/ml to 1200 IU/ml.

3. The composition according to claim 1, wherein the follicle stimulating hormone is present in an amount of from 300 IU/ml to 900 IU/ml.

4. The composition according to claim 1, wherein the follicle stimulating hormone is present in an amount of about 600 IU/ml.

5. The composition according to claim 1, wherein the follicle stimulating hormone is human follicle stimulating hormone.

6. The pharmaceutical composition according to claim 1, wherein the follicle stimulating hormone is urinary human follicle stimulating hormone.

7. The composition according to claim 1, wherein the follicle stimulating hormone is recombinant human follicle stimulating hormone.

8. The composition according to claim 1, further comprising sucrose.

9. The composition according to claim 1, further comprising methionine.

10. The composition according to claim 1, further comprising a phosphate buffer, wherein the pH of the composition is from 6.0 to 8.0.

11. The composition according to claim 1, further comprising a phosphate buffer, wherein the pH of the composition is about 7.0.

12. The composition according to claim 1, comprising the diluent, recombinant follicle stimulating hormone, poloxamer 188, sucrose, methionine, m-cresol, and an aqueous buffer, and wherein the pH of the composition is about 7.0.

13. The composition according to claim 12, wherein the recombinant follicle stimulating hormone is present in an amount of about 600 IU/ml, the poloxamer 188 is present in an amount of about 0.1 mg/ml, the sucrose is present in an amount of about 60 mg/ml, the methionine is present in an amount of about 0.1 mg/ml, the m-cresol is present in an amount of about 3 mg/ml, and the phosphate buffer is present in an amount of about 10 mM in phosphate.

14. The composition according to claim 1, wherein the diluent is water for injection.

15. A liquid pharmaceutical composition, comprising: a follicle stimulating hormone, a luteinising hormone, a bacteriostatic agent selected form the group consisting of phenol and m-cresol, poloxamer 188, and a diluent wherein either the follicle stimulating hormone is human follicle stimulating hormone, or the luteinising hormone is human luteinising hormone, or both the follicle stimulating hormone is human follicle stimulating hormone and the luteinising hormone is human luteinising hormone, the composition having a stability sufficient to avoid precipitation.

16. A liquid pharmaceutical composition, comprising: a follicle stimulating hormone, a luteinising hormone, a bacteriostatic agent selected form the group consisting of phenol and m-cresol, poloxamer 188, and a diluent wherein either the follicle stimulating hormone is urinary human follicle stimulating hormone, or the luteinising hormone is urinary human luteinising hormone, or both the follicle stimulating hormone is urinary human follicle stimulating hormone and the luteinising hormone is urinary human luteinising hormone, the composition having a stability sufficient to avoid precipitation.

17. A liquid pharmaceutical composition, comprising: a follicle stimulating hormone, a luteinising hormone, a bacteriostatic agent selected form the group consisting of phenol and m-cresol, poloxamer 188, and a diluent wherein either the follicle stimulating hormone is recombinant human follicle stimulating hormone, or the luteinising hormone is recombinant human luteinising hormone, or both the follicle stimulating hormone is recombinant human follicle stimulating hormone and the recombinant luteinising hormone is human luteinising hormone, the composition having a stability sufficient to avoid precipitation.

18. The composition according to claim 15, wherein the follicle stimulating hormone and the luteinising hormone are present in a ratio of from 6:1 to 1:6.

19. The composition according to claim 15, wherein the follicle stimulating hormone and the luteinising hormone are present in a ratio of from 4:1 to 1:2.

20. The composition according to claim 15, wherein the follicle stimulating hormone and the luteinising hormone are present in a ratio of from 3:1 to 1:1.

21. The composition according to claim 15, wherein the follicle stimulating hormone and the luteinising hormone are present in a ratio of from 2:1 to 1:1.

22. The composition according to claim 15, in which the bacteriostatic agent is phenol.

23. The composition according to claim 15, in which the bacteriostatic agent is m-cresol.

24. The composition according to claim 15, further comprising sucrose.

25. The composition according to claim 15, further comprising methionine.

26. The composition according to claim 15, further comprising a phosphate buffer, wherein the pH of the composition is from 6.0 to 8.0.

27. The composition according to claim 15, further comprising a phosphate buffer, wherein the pH of the composition is about 7.0.

28. The composition according to claim 15, comprising the diluent, recombinant follicle stimulating hormone, luteinising hormone, poloxamer 188, sucrose, methionine, phenol, and an aqueous buffer, wherein the pH of the composition is about 7.0.

29. The composition according to claim 28, wherein the recombinant follicle stimulating hormone is present in an amount of about 600 IU/ml, the poloxamer 188 is present in an amount of about 0.1 mg/ml, the sucrose is present in an amount of about 60 mg/ml, the methionine is present in an amount of about 0.1 mg/ml, the phenol is present in an amount of about 3 mg/ml, and the buffer is a phosphate buffer present in an amount of about 10 mM in phosphate.

30. The composition according to claim 15, wherein the diluent is water for injection.

31. The composition according to claim 15, wherein the diluent is at least one of water and a mixture of water and a solvent miscible with water.

32. The composition according to claim 15, wherein the follicle stimulating hormone is present in an amount of from 150 IU/ml to 1200 IU/ml.

33. The composition according to claim 15, wherein the follicle stimulating hormone is present in an amount of from 300 IU/ml to 900 IU/ml.

34. The composition according to claim 15, wherein the follicle stimulating hormone is present in an amount of about 600 IU/ml.

35. The composition according to claim 15, wherein the luteinising hormone is present in an amount of from 150 IU/ml to 1200 IU/ml.

36. The composition according to claim 15, wherein the luteinising hormone is present in an amount of from 300 IU/ml to 750 IU/ml.

37. The composition according to claim 28, wherein the luteinising hormone is recombinant luteinising hormone.

38. The composition according to claim 37, wherein the follicle stimulating hormone and the luteinising hormone are present in a ratio of from 2:1.

39. The composition according to claim 38, wherein the buffer is a phosphate buffer.

40. A liquid pharmaceutical composition, comprising: a follicle stimulating hormone, phenol, a diluent, and poloxamer 188, the composition having a stability sufficient to avoid precipitation.

41. The composition according to claim 40, wherein the follicle stimulating hormone is present in an amount of from 150 IU/ml to 1200 IU/ml.

42. The composition according to claim 40, wherein the follicle stimulating hormone is present in an amount of from 300 IU/ml to 900 IU/ml.

43. The composition according to claim 40, wherein the follicle stimulating hormone is present in an amount of about 600 IU/ml.

44. The composition according to claim 40, wherein the follicle stimulating hormone is human follicle stimulating hormone.

45. The pharmaceutical composition according to claim 40, wherein the follicle stimulating hormone is urinary human follicle stimulating hormone.

46. The composition according to claim 40, wherein the follicle stimulating hormone is recombinant human follicle stimulating hormone.

47. The composition according to claim 40, further comprising sucrose.

48. The composition according to claim 40, further comprising methionine.

49. The composition according to claim 40, further comprising a phosphate buffer, wherein the pH of the composition is from 6.0 to 8.0.

50. The composition according to claim 40, further comprising a phosphate buffer, wherein the pH of the composition is about 7.0.

51. The composition according to claim 40, wherein the diluent is water for injection.

52. The composition according to claim 40, wherein the diluent is at least one of water and a mixture of water with a solvent miscible with water.

53. The composition according to claim 1 consisting essentially of recombinant follicle stimulating hormone, m-cresol, diluent, poloxamer 188, sucrose, methionine, and phosphate buffer.

54. The composition according to claim 53, wherein the recombinant follicle stimulating hormone is present in an amount of about 600 IU/ml, the m-cresol is present in an amount of about 3 mg/ml, the poloxamer 188 is present in an amount of about 0.1 mg/ml, the sucrose is present in an amount of about 60 mg/ml, the methionine is present in an amount of about 0.1 mg/ml, and the phosphate buffer is present in an amount of about 10 mM in phosphate.

55. The composition according to claim 15 consisting essentially of the diluent, recombinant follicle stimulating hormone, recombinant luteinising hormone, phenol, diluent, poloxamer 188, sucrose, methionine, and phosphate buffer.

56. The composition according to claim 55, wherein the recombinant follicle stimulating hormone is present in an amount of about 600 IU/ml, the recombinant luteinising hormone is present in an amount of about 300 IU/ml, the poloxamer 188 is present in an amount of about 0.25 mg/ml, the sucrose is present in an amount of about 77 mg/ml, and the methionine is present in an amount of about 0.15 mg/ml.

57. The composition according to claim 40, comprising the diluent, recombinant follicle stimulating hormone, phenol, poloxamer 188, sucrose, methionine, and an aqueous buffer, and wherein the pH of the composition is about 7.0.

58. The composition according to claim 40 consisting essentially of the diluent, recombinant follicle stimulating hormone, phenol, poloxamer 188, sucrose, methionine, and an aqueous buffer, and wherein the pH of the composition is about 7.0.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc